Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation (Q39438493)

12 September 2017

Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation (English)

1 reference

12 September 2017

Yan Yang

1

1 reference

12 September 2017

Qing Huang

2

1 reference

12 September 2017

Yanjun Lu

3

1 reference

12 September 2017

Xiaoqing Li

4

1 reference

12 September 2017

Shiang Huang

5

1 reference

12 September 2017

1 April 2012

1 reference

Journal of Cellular Biochemistry

12 September 2017

1 reference

12 September 2017

113

1 reference

12 September 2017

4

1 reference

12 September 2017

1314-1322

1 reference

Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML.

12 September 2017

1 reference

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).

21 January 2018

1 reference

Inhibitors of protein phosphatases 1 and 2A differentially prevent intrinsic and extrinsic apoptosis pathways

21 January 2018

1 reference

Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation

21 January 2018

1 reference

A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial

21 January 2018

1 reference

Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin

21 January 2018

1 reference

Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.

21 January 2018

1 reference

PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.

21 January 2018

1 reference

FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies

21 January 2018

1 reference

Inhibition of PP2A by LIS1 increases HIV-1 gene expression

21 January 2018

1 reference

The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia.

21 January 2018

1 reference

PP2A-mediated dephosphorylation of p107 plays a critical role in chondrocyte cell cycle arrest by FGF

21 January 2018

1 reference

Detection of an activating c-kit mutation by real-time PCR in patients with anaphylaxis

21 January 2018

1 reference

The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A

21 January 2018

1 reference

FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma

21 January 2018

1 reference

Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms

21 January 2018

1 reference

KIT mutations confer a distinct gene expression signature in core binding factor leukaemia

21 January 2018

1 reference

Clinical implications of c-Kit mutations in acute myelogenous leukemia.

21 January 2018

1 reference

Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.

21 January 2018

1 reference

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein

21 January 2018

1 reference

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

21 January 2018

1 reference

The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors

21 January 2018

1 reference

The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.

21 January 2018

1 reference

Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study

21 January 2018

1 reference

May the correlation between Kit-D816 mutation and AML1-ETO level change the use of prognostic factors in t(8;21) AML?

21 January 2018

1 reference

Cooperating gene mutations in acute myeloid leukemia: a review of the literature.

21 January 2018

1 reference

Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers

21 January 2018

1 reference

Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor

21 January 2018

1 reference

Optimal induction and post-remission therapy for AML in first remission

21 January 2018

1 reference

Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients

21 January 2018

1 reference

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival

21 January 2018

1 reference

Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples

21 January 2018

1 reference

Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits

21 January 2018

1 reference

KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups

21 January 2018

1 reference

The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction

21 January 2018

1 reference

Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.

21 January 2018

1 reference

Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis

21 January 2018

1 reference

AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.

21 January 2018

1 reference

Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCB.24003

1 reference

12 September 2017

1 reference